403
Sorry!!
Error! We're sorry, but the page you were looking for doesn't exist.
Novavax Swings To Profit In Q4 Fueled By Nuvaxovid-Linked Revenue
(MENAFN- AsiaNet News)
Novavax, Inc. (NVAX) reported a sharp increase in fourth-quarter (Q4) and 2025 revenue as the vaccine maker leaned on partnership income, cost cuts and product sales.
The Maryland-based biotech generated $147 million in revenue during Q4, a 67% year-on-year (YoY) increase. Earnings per share (EPS) for the quarter were $0.11. Both the metrics surpassed the analysts' consensus estimates of $90.26 million and a loss of $0.55, respectively, according to Fiscal AI data.
Annual revenue surged 65% YoY to $1.12 billion, driven in large part by $625 million in Nuvaxovid sales linked primarily to settlements of earlier advance purchase deals.
Following the update, Novavax stock traded over 1% higher in Thursday's premarket.
Get updates to this developing story directly on Stocktwits.
Legal Disclaimer:
MENAFN provides the
information “as is” without warranty of any kind. We do not accept
any responsibility or liability for the accuracy, content, images,
videos, licenses, completeness, legality, or reliability of the information
contained in this article. If you have any complaints or copyright
issues related to this article, kindly contact the provider above.
Most popular stories
Market Research
More Story
Comments
No comment